← All indications
Warts
Benign epidermal proliferations or tumors; some are viral in origin.
Subtype terms (2)
More specific conditions that are subtypes of Warts in the MeSH hierarchy.
- Condylomata Acuminata
45 drugs (20 approved, 25 experimental)
- Epidermodysplasia Verruciformis
Drugs by status
Approved for this indication (5)
Phase 4 trials (13)
Phase 3 trials (18)
Phase 2 trials (25)
Phase 1 trials (7)
Organizations
Organization Involved with Phase 4 Indications (15)
- Meda
- MediGene
- Grossman, Michael, D.P.M.
- Main Line Health
- Wayne State University
- Assiut University
- University of British Columbia
- University of California, San Francisco
- Provincial Health Services Authority
- CHU AMBROISE PARE
- University of Paris
- Society of Dermatology and venerology
- ORION Sante
- St. Vincents Hospital Manhattan
- The University of Texas, Dallas
Organization Involved with Phase 3 Indications (15)
- Aclaris Therapeutics, Inc.
- Merck
- Catalysis SL
- Cutanea Life Sciences, Inc.
- Graceway
- bioRASI, LLC
- Centro Dermatológico Dr. Ladislao de la Pascua
- Huazhong University of Science and Technology
- University of Pretoria
- Isfahan University
- Stellenbosch University
- Assistance Publique - Hôpitaux de Paris
- Hyloris Developments SA
- Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri
- Calox
Organization Involved with Phase 2 Indications (32)
- PPD
- ProStraken
- ALC Therapeutics, LLC
- Novartis
- Anaconda Pharma
- BioMAS Ltd
- G&E Herbal Biotechnology Co., LTD
- Nielsen BioSciences, Inc.
- Novan, Inc.
- Nowarta Biopharma Inc
- Veloce BioPharma LLC
- Verrica Pharmaceuticals Inc.
- ViroXis Corporation
- NatImmune A/S
- National Cheng Kung University
- University of Aberdeen
- Zagazig University
- Mayo Clinic
- University of Copenhagen
- University of Minnesota
- RXi Pharmaceuticals
- Philadelphia Institute of Dermatology
- Technion University
- Dr. Reddy's Laboratories
- Indiana Clinical Trials Center
- Erasmus University Rotterdam
- Paidion Research, Inc
- Instat services
- BioClinica, Inc.
- Leo Pharma
- +2 more
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (8)